Treat to Target (T2T) in Gout Trial

 
 

Due to COVID-19 (Coronavirus), as of Monday 23rd March 2020, recruitment of patients to all of our active research studies has ceased. This is to allow our clinical colleagues to focus on their care where it is most needed. Keele Clinical Trials Unit will be operating remotely. We are currently reviewing the trials we have open and are in contact with sponsors. The safety of our patients is always our priority. We apologise for any inconvenience caused during this challenging time. You can continue to contact us using individual staff email addresses or by using your usual study contact email address, to contact study teams. Should you have any other queries or questions please use the general Keele CTU enquiry email -  ctu.operations@keele.ac.uk 


 

The T2T trial is a randomised controlled trial (RCT) designed to test the clinical and cost-effectiveness of using a goal-directed allopurinol-based-treat to target approach in people with recurrent gout flares.

The T2T trial is working with clinical research networks and GP practices in the UK in the regions of East Midlands, West Midlands and Wessex.

The website will be used as a communication hub for sites and trained staff.

Study Title  What is the clinical effectiveness of using a goal-directed allopurinol-based treat to target protocol in people with recurrent gout flares? 
Short Title T2T
Chief Investigator Dr A Abhishek
Sponsor University of Nottingham
IRAS Number  263669
REC Number  19/NW/0310
ISRCTN 12059648
CPMS 42053
Funder NIHR Health Technology Assessment (HTA)
Grant Number

17/82/02

Trial management

Keele Clinical Trials Unit, Tel: +44 (0)1782 732950, E-mail: sch-tr.t2tgout@nhs.net

Privacy Policy

Keele University is the joint data controller with the University of Nottingham for the T2T study data, and hence require that Keele University and University of Nottingham privacy notices are made available to individual requests for information about how we process any personal information about an individual. 

Funding Notice

This study is funded by the National Institute for Health Research (NIHR) [Health Technology Assessment (HTA) programme (17/82/02)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Contact Us

Telephone: +44 (0)1782 732950
Email: sch-tr.t2tgout@nhs.net